TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 13nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 23nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 30nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 38nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 38nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 49nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 55nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 60nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 79nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 81nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 84nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 100nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 110nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 110nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 120nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 140nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 160nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 170nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 180nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 190nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 190nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 190nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 250nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 270nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 300nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 310nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 310nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 410nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 410nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 450nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 530nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 590nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.10E+3nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 1.50E+3nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 3.00E+3nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: 3.90E+3nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair
TargetGlutamate receptor ionotropic, NMDA 1/2B(Homo sapiens (Human))
Sage Therapeutics
Curated by ChEMBL
Sage Therapeutics
Curated by ChEMBL
Affinity DataEC50: >1.00E+4nMAssay Description:Positive allosteric modulation of recombinant human GluN1/GluN2B receptor stably expressed in HEK293 cells assessed as increase in glycine/L-glutamat...More data for this Ligand-Target Pair